5-Fluorouracil prodrug, ftorafur, modulated by uracil (UFT): Preclinical and clinical prospective

Tumori

Volumn 83, Issue 1 SUPPL., 1997, Pages

  Cao, Shousong ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; FOLINIC ACID; OXONIC ACID; PRODRUG; SPARFOSIC ACID; TEGAFUR; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0030962292     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/03008916970831s139     Document Type: Conference Paper

References (34)

1. Bedikian A.Y., Bodey G.P., Valdivieso M., Burgess M.A.: Phase I evaluation of oral tegafur, Cancer Treat. Rep., 67: 81-84, 1983.
2. Cao S., Durrani F., Maue R., Rustum Y.M.: Modulation of the antitumor activity of ftorafur (FT) and uracil (U)-Ft combination (UFt) in rats bearing advanced colon carcinoma, Proc. Am. Soc. Clin. Oncol., 12: 212, 1993.
3. Cao S., Frank C., Shirasaka T., Rustum Y.: 5-fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clinical Cancer Research., 1: 839-845, 1995.
4. Cao S., Rustum Y.M., Spector T.: 5-ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Research., 54: 1507-1510, 1994.
5. Danhauser L.L., Rustum Y.M.: A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combinations. J. Lab. & Clin. Med., 93: 1047-1053, 1979.
6. Friedman M.A., Ignoffo R.J.: A review of the United States clinical experience of the fluoropyrimidine ftorafur (NS-C148958. Cancer Treat. Rev., 7: 205-213, 1980.
7. Fukui Y., Imabayashi N., Nishii M.: Clinical study on the enhancement of drug delivery into tumor tissue by UFT. Jpn. J. Cancer Chemother., 7: 2124-2129, 1980.
8. Fujii S., Kitano S., Ikenaka K., Shirasaka T.: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann., 70: 209-214, 1978.
9. Fujii S., Kitano S., Ikenaka K., Shirasaka T.: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents., Gann., 70: 209-214, 1979.
10. Hines J.D., Zakem M.H., Adelstein D.J., Giroski P., Blum M.R., Rustum Y.M.: Bioavailability of high-dose oral leucovorin, NCI Monographs, 57-60, 1987.
11. Ho D.H., Prazdur R., Covington W., Brown N., Lassere Y., Lin S., Rustum Y., Creaven P., Newman R.A., Krakoff I., Kuritani: Correlation of pharmacokinetics of FU with toxicity of patients treated orally with uracil and ftorafur (4:1 molar ratio) + leucovorin. Proc. Am. Assoc. Cancer Res., 35: 241, 1994.
12. Jaiyesimi I., Pazdur R., Ho D.H., Lassere Y., Moore D. Jr., Bready B., Krakoff I.H.: Phase 1 trial of UFT (ftorafur plus uracil) and leucovorin: 28 day schedule. Proc. Am. Soc. Clin. Oncol., 12: 152, 1993.
13. Jaiyesimi I., Pazdur R., Rhodes V., Lassere Y., Soo E., Bready B.: Phase I study of tegafur plus uracil co-administered with oral leucovorin. Proc. Am. Soc. Clin. Oncol., 13: 164, 1994.
14. Kimura K., Suga S., Shimaji T., Kitamura M., Suzuoki Y., lsobe K.: Clinical basis of chemotherapy for gastric cancer with uracil and 1(2′-tetrahydrofuryl)-5-fluorouracil. Gastroenterol. Jpn., 15: 324-329, 1980.
15. Kohne-Wompner C.H., Schmoll H.J., Harstrick A., Rustum Y.M.: Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin. Oncol., 19: 105-125, 1992.
16. Kubota Y., Hosaka M., Fukushima S., Kondo I.: Prophylactic oral UFT therapy for superficial bladder cancer. Cancer, 71: 1842-1845, 1993.
17. Maehara Y., Kusumoto T., Kusumoto H., Anai H., Sugimachi K.: UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, (1-2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil. Chemotherapy, 34: 484-489, 1988.
18. Maechara Y., Kusumoto T., Kusumoto H., Anai H., Sakaguchi Y., Kiddo Y., Okamura T., Korenaga D., Sugimachi, K.: 5-fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase. Cancer, 63: 1693-1696, 1989.
19. Malik S.T.A., Talbot D., Clarke P.I., Osborne R., Reznek R., Wrigley P.F.M., Slevin M.L.: Phase II trial of UFT in advanced colorectal and gastric cancer. Br. J. Cancer, 62: 1023-1025, 1990.
20. Meropol N.J., Creaven P.J., Petrelli N.J., Rodiguez-Bioas M., Frank C., Ho D.H., Rustum Y.M.: A phase I and pharmacokinetics study of oral UFT and leucovorin (LV). Proc. Am. Soc. Clin. Oncol., 13: 160, 1994.
21. Ota K., Taguchi T., Kimura K.: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988.
22. Pazdur R., Lassere Y., Rhodes V., Ajani J.A., Sugarman S.M., Patt Y.Z., Jones D.V. Jr, Markowitz A.B., Abbruzzese J.L., Bready B., Levin B.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
23. Piedbois P., Buyse M., Rustum Y., Machover D., Erlichman C., Carlson R.W., Valone F., Labianca R., Doroshow J.H., Petrelli N.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
24. Porter D.J.T., Chestnut W.G., Merrill B.M., Spector T.: Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J. Biol. Chem., 267: 5236-5242, 1992.
25. Rustum Y.M.: Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. Cancer, 63: 1013-1017, 1989.
26. Rustum Y.M., Cao S., Spector T.: 5-ethynyluracil (776C85) is a potent modulator of the therapeutic activity of 5-fluorouracil. Proc. Am. Assoc. Cancer Res., 34: 283, 1993.
27. Shirasaka T., Nakano K., Takechi T., Satake H., Uchida J., Fujioka A., Saito H., Okabe H., Oyama K., Takeda S., Unemi N., Fukushima M.: Antitumor activity of IM tegafur-0.4 M 5-chloro-2-4-dihydroxypyrimidine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56: 2602-2606, 1996.
28. Spector T.: 5-ethynyluracil (776C85): an inactivator of uracil reductase that potentiates the antitumor activity of 5-fluorouracil. Curr. Opin. Ther. Patients, 3: 1751-1754, 1993.
29. Spector T., Harrington J.A., Porter D.J.T.: 5-ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem. Pharmacol., 46: 2243-2248, 1993.
30. Taguchi T., Nakano Y., Fuji S., Shirasaka T.: Determination of 5-fluorouracil levels in tumors, blood and other tissues. Cancer Chemother., 5: 1167-1172, 1978.
31. Taguchi T., Nakano Y., Jikuya K., Fujii S., Ikenaka K., Fukushima M., Shirasaka T.: Effect of uracil on the antitumor activity of ftoraful. Gan To Kagaku Ryoho, 5: 1161-1163, 1978.
32. Toide H., Aklyoshi H., Minato Y., Okuda H., Fujii S.: Comparative studies on metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann., 68: 553-560, 1977.
33. Unemi N., Takeda S., Tajima K., Kawaguchi Y., Yasuda A.: Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil. Chemotherapy, 29: 164-175, 1981.
34. Zhang Z.G., Harstrick A., Rustum Y.M.: Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin. Oncol., 19: 10-15, 1992.